See more : BitFuFu Inc. Warrant (FUFUW) Income Statement Analysis – Financial Results
Complete financial analysis of Rani Therapeutics Holdings, Inc. (RANI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Rani Therapeutics Holdings, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- SRV Yhtiöt Oyj (SRV1V.HE) Income Statement Analysis – Financial Results
- Quorum Information Technologies Inc. (QIS.V) Income Statement Analysis – Financial Results
- Seoul City Gas Co., Ltd. (017390.KS) Income Statement Analysis – Financial Results
- Terna – Rete Elettrica Nazionale Società per Azioni (TRN.MI) Income Statement Analysis – Financial Results
- Empiric Student Property plc (EPCFF) Income Statement Analysis – Financial Results
Rani Therapeutics Holdings, Inc. (RANI)
About Rani Therapeutics Holdings, Inc.
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 2.72M | 462.00K | 979.00K |
| Cost of Revenue | 822.00K | 1.31M | 0.00 | 0.00 | 0.00 |
| Gross Profit | -822.00K | -1.31M | 2.72M | 462.00K | 979.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 39.62M | 36.61M | 26.48M | 12.04M | 24.58M |
| General & Administrative | 26.48M | 26.84M | 27.83M | 4.96M | 3.47M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 26.48M | 26.84M | 27.83M | 4.96M | 3.47M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 66.10M | 63.45M | 54.32M | 17.01M | 28.04M |
| Cost & Expenses | 66.10M | 63.45M | 54.32M | 17.01M | 28.04M |
| Interest Income | 3.30M | 1.25M | 89.00K | 63.00K | 423.00K |
| Interest Expense | 5.09M | 1.07M | 466.00K | 124.00K | 10.00K |
| Depreciation & Amortization | 822.00K | 1.31M | 497.00K | 589.00K | 564.00K |
| EBITDA | -65.28M | -60.89M | -52.08M | -15.96M | -26.01M |
| EBITDA Ratio | 0.00% | 0.00% | -1,895.84% | -3,439.83% | -2,663.74% |
| Operating Income | -66.10M | -63.45M | -51.60M | -16.54M | -27.07M |
| Operating Income Ratio | 0.00% | 0.00% | -1,899.12% | -3,580.95% | -2,764.56% |
| Total Other Income/Expenses | -1.78M | 177.00K | -1.45M | -124.00K | 478.00K |
| Income Before Tax | -67.88M | -63.27M | -53.05M | -16.67M | -26.59M |
| Income Before Tax Ratio | 0.00% | 0.00% | -1,952.41% | -3,607.79% | -2,715.73% |
| Income Tax Expense | 0.00 | 70.00K | 41.00K | 35.00K | 10.00K |
| Net Income | -33.97M | -63.34M | -53.09M | -16.70M | -26.60M |
| Net Income Ratio | 0.00% | 0.00% | -1,953.92% | -3,615.37% | -2,716.75% |
| EPS | -1.33 | -2.66 | -2.69 | -0.85 | -1.35 |
| EPS Diluted | -1.33 | -2.66 | -2.69 | -0.85 | -1.35 |
| Weighted Avg Shares Out | 25.51M | 23.82M | 19.71M | 19.74M | 19.74M |
| Weighted Avg Shares Out (Dil) | 25.51M | 23.82M | 19.71M | 19.74M | 19.74M |
Rani Therapeutics Announces Closing of its Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Rani Therapeutics' $73M IPO will fund upcoming clinical trials
Rani Therapeutics Debuts On The Nasdaq: What You Should Know About The Biopharma
Rani Therapeutics Announces Pricing of Initial Public Offering
Source: https://incomestatements.info
Category: Stock Reports